Tredje AP fonden Takes $33.62 Million Position in Pfizer Inc. $PFE

Tredje AP fonden bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,350,000 shares of the biopharmaceutical company’s stock, valued at approximately $33,615,000.

Several other institutional investors have also added to or reduced their stakes in PFE. Larson Financial Group LLC boosted its stake in shares of Pfizer by 3.1% during the 4th quarter. Larson Financial Group LLC now owns 135,516 shares of the biopharmaceutical company’s stock worth $3,374,000 after acquiring an additional 4,109 shares during the last quarter. Gables Capital Management Inc. increased its stake in shares of Pfizer by 1.4% in the 4th quarter. Gables Capital Management Inc. now owns 36,611 shares of the biopharmaceutical company’s stock worth $912,000 after purchasing an additional 500 shares in the last quarter. Hartford Funds Management Co LLC increased its stake in shares of Pfizer by 14.5% in the 4th quarter. Hartford Funds Management Co LLC now owns 36,230 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 4,599 shares in the last quarter. Csenge Advisory Group increased its stake in shares of Pfizer by 11.6% in the 4th quarter. Csenge Advisory Group now owns 152,390 shares of the biopharmaceutical company’s stock worth $3,795,000 after purchasing an additional 15,809 shares in the last quarter. Finally, Profund Advisors LLC increased its stake in shares of Pfizer by 19.7% in the 4th quarter. Profund Advisors LLC now owns 102,174 shares of the biopharmaceutical company’s stock worth $2,544,000 after purchasing an additional 16,785 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PFE. Bank of America reduced their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. CICC Research began coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.84.

Pfizer Trading Down 0.1%

Shares of Pfizer stock opened at $25.31 on Tuesday. The company has a market capitalization of $144.22 billion, a P/E ratio of 19.32 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a fifty day moving average of $26.96 and a 200 day moving average of $26.20. Pfizer Inc. has a fifty-two week low of $22.64 and a fifty-two week high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.